| UCR01978 |
(S)-3-hydroxy-3-methylglutaryl-CoA + CoA = H(2)O + acetoacetyl-CoA + acetyl-CoA |
None - {{∅}} |
None - {{∅}} |
Unexplained |
|
| UCR02082 |
(R)-mevalonate + CoA + 2 NADP(+) = (S)-3-hydroxy-3-methylglutaryl-CoA + 2 H(+) + 2 NADPH |
None - {{∅}} |
None - {{∅}} |
Unexplained |
|
| UER00103 |
(R)-mevalonate from acetyl-CoA: step 3/3~1 (S)-3-hydroxy-3-methylglutaryl-CoA + 2 H(+) + 2 NADPH => 1 (R)-mevalonate + 1 CoA + 2 NADP(+). |
None - {{∅}} |
None - {{∅}} |
Unexplained |
|
| UER00101 |
(R)-mevalonate from acetyl-CoA: step 1/3~2 acetyl-CoA => 1 CoA + 1 acetoacetyl-CoA. |
None - {{∅}} |
True - {{t}} |
Unconfirmed presence |
|
| UPA00058 |
(R)-mevalonate biosynthesis~Biosynthesis of mevalonic acid, a six-carbon metabolic intermediate. In eukaryotes, it arises from linkage of two acetyl-CoAs in the mitochondrion to form acetaoacetyl-CoA (4 carbons), followed by addition of another acetyl group from a third acetyl-CoA to give 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA). This latter compound is reduced by HMG-CoA reductase in the endoplasmic reticulum, using two NADPHs, with coincident loss of CoASH. HMG-CoA reductase is the most important regulatory enzyme for the cholesterol biosynthetic pathway and other isoprenoids/terpenoids. HMG-CoA reductase is a target for drugs that attempt to lower cholesterol levels in the body. One such drug is lovastatin, which inhibits the enzyme and stops endogenous synthesis of cholesterol. |
None - {{∅}} |
None - {{∅},{t}} |
Unexplained |
|
| ULS00039 |
(R)-mevalonate from acetyl-CoA |
None - {{∅}} |
None - {{∅},{t}} |
Unexplained |
|
| UCR00238 |
2 acetyl-CoA = CoA + acetoacetyl-CoA |
None - {{∅}} |
True - {{t}} |
Unconfirmed presence |
|
| UER00102 |
(R)-mevalonate from acetyl-CoA: step 2/3~1 H(2)O + 1 acetoacetyl-CoA + 1 acetyl-CoA => 1 (S)-3-hydroxy-3-methylglutaryl-CoA + 1 CoA. |
None - {{∅}} |
None - {{∅}} |
Unexplained |
|